Science 1st - Designing Nucleic Acid Medicines
UCSF - Byers Auditorium, Genentech Hall , 600 16th St , San Francisco , CA 94158
January 28, 2016 from 09:30 AM to 13:00 PM (PDT)
$10 - $35
We are closer than ever to realizing the promise of medicines that address a diversity of human maladies by supporting, supplanting, or suppressing the genetic expression patterns within a patient’s cells. Whether the goal is to provide new genetic expression to the cell or to modulate existing expression, we must learn how to dose these new medicines to provide meaningful therapeutic indexes. To achieve that, we must understand the fundamental control mechanisms of gene expression exercised through a diversity of players including RNAs, DNA domains, and proteins that act upon chromatin or transcripts.
Johnson & Johnson Innovation, JLABS (JLABS) is bringing together leading Bay Area scientific experts to share their data and insights advancing our understanding in this fascinating and complex space.
- Tissue and Development - specific Control
- Regulatory RNAs
- Vectors and Delivery to Patients
8:30am | Registration Opens, Networking and Breakfast
9:25am | Introduction
9:30am | Presentation and Q&A
11:15am | Panel Discussion and Q&A
11:45am | Close
Michael McManus | Associate Professor, UCSF School of Medicine read bio»
David Schaffer | Professor, Chemical and Biomolecular Engineering, Bioengineering, Molecular and Cell Biology, UC Berkeley / Director, Berkeley Stem Cell Center read bio»
Laura Sepp-Lorenzino | VP, Entrepreneur-in-Residence, Alnylam Pharmaceuticals read bio»
[moderator] Beth Hill | Senior Director, Platform Innovation, Johnson & Johnson Innovation read bio»
$25 General Public - pre-registration will remain open until 5:00pm on Jan 27th
$15 Student/Academic - pre-registration will remain open until 5:00pm on Jan 27th
$35 At the door - at the door registration will open at 8:30pm on Jan 28th
UCSF - Byers Auditorium, Genentech Hall
600 16th St
San Francisco, CA 94158
About the Science First series:
The Science First series, sponsored by Johnson & Johnson Innovation, JLABS, brings together top experts to explore pressing topics in their scientific field. It is a chance for local scientists, researchers, and entrepreneurs to present and dialogue on new discoveries, advancing techniques, and other cutting-edge science themes.
Michael McManus, Ph.D. | Associate Professor, UCSF School of Medicine
Dr. McManus obtained his Ph.D. from the University of Alabama in Birmingham, where he studied RNA editing in the laboratory of Stephen L. Hajduk. In 2000, he did his postdoctoral training as a Cancer Research Institute fellow, in the laboratory of Nobel Laureate Phillip A. Sharp at the Massachusetts Institute of Technology (MIT), studying the role of RNA-interference pathways in mammals. He is appointed as an Associate Professor at the University of California San Francisco, in the Department of Microbiology and Immunology. He is the founder and Director of the W.M. Keck Center for Noncoding RNAs and also oversees the Sandler Lentiviral RNAi Core at UCSF. He has a long-standing interest in post-transcriptional gene regulation and the role of small RNAs in gene expression.
David Schaffer, Ph.D. | Professor, Chemical and Biomolecular Engineering, Bioengineering, Molecular and Cell Biology, University of California at Berkeley / Director, Berkeley Stem Cell Center
David Schaffer is a Professor of Chemical and Biomolecular Engineering, Bioengineering, and Neuroscience at University of California, Berkeley, where he also serves as the Director of the Berkeley Stem Cell Center. He graduated from Stanford University with a B.S. degree in Chemical Engineering, and from Massachusetts Institute of Technology with a Ph.D. in Chemical Engineering. He did a postdoctoral fellowship in the laboratory of Fred Gage at the Salk Institute for Biological Studies in La Jolla, CA. At UC Berkeley, Dr. Schaffer applies engineering principles to enhance stem cell and gene therapy approaches for neuroregeneration, work that includes novel approaches for molecular engineering and evolution of new viral vectors as well as new technologies to investigate and control stem cell fate decisions.
Connect with David:
Laura Sepp-Lorenzino, Ph.D. | VP, Entrepreneur-in-Residence, Alnylam Pharmaceuticals
Laura Sepp-Lorenzino, Ph.D. is Entrepreneur-in-Residence at Alnylam Pharmaceuticals, a leading Cambridge MA biopharmaceutical company developing novel therapeutics based on RNA interference. Dr. Sepp-Lorenzino joined Alnylam in 2014, and is leading the Hepatic Infectious Disease Strategic Therapeutic Area. Before joining Alnylam, Dr. Sepp-Lorenzino spent 14 years at Merck & Co., having most recently served as Executive Director and Department Head, RNA Therapeutics Discovery Biology. In this role, she was responsible for identification and optimization of siRNAs and delivery vehicles, advancement of pre-clinical candidates, and development of an siRNA-conjugate platform to expand the repertoire of tissues accessible to in vivo siRNA delivery. Prior to RNAi, Laura worked in oncology drug discovery and development, having led the Cancer Research Department at Merck West Point, and having been an Assistant Lab Member at Memorial Sloan-Kettering Cancer Center. Laura received her Professional Degree in Biochemistry from the University of Buenos Aires, and her M.S. and Ph.D. in Biochemistry from New York University.
Connect with Laura:
[moderator] Beth Hill, Ph.D. | Senior Director, Platform Innovation, Johnson & Johnson Innovation
Beth Hill is Senior Director of Platform Innovation at Johnson & Johnson Innovation, California. She is an experienced pharmaceutical innovator with many years of strategic and operational leadership in creating and applying technologies that overcome technical and business barriers. Formerly with Janssen R&D, Beth led global cross-disciplinary functions working from late discovery through development and commercialization with a focus on drug delivery and drug+device combination products. Beth has also led R&D teams to develop therapeutics for cancer and autoimmune disease. At Systemix /Novartis she held functional and project leadership roles in stem, somatic cell and gene therapies. She began her industrial career developing antibody-based diagnostics at Syva Co. Beth earned her BA in Medical Technology at Augustana College, her PhD in Microbiology at Columbia University, and completed her post-doctoral studies in the Stanford Department of Structural Biology.
Connect with Beth: